Chinese Expert Consensus on the Clinical Application of Finerenone in Geriatric Comorbidities

Dysregulation of the renin-angiotensin-aldosterone system (RAAS) constitutes a pivotal factor in the onset and progression of various geriatric diseases, including cardiovascular diseases, diabetes, and chronic kidney disease (CKD), all closely linked to adverse cardiorenal outcomes in older patients. Excessive activation of the mineralocorticoid receptor (MR) drives inflammation, fibrosis, and oxidative stress across tissues and organs, representing a fundamental mechanism underlying systemic metabolic disorders, diabetes, cardiovascular diseases, and kidney pathologies. Emerging clinical evidence indicates that the non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone can block MR with high selectivity, significantly reducing cardiorenal event risks in older patients and thereby enhancing overall health status. This offers a novel therapeutic avenue for the long-term management of older patients burdened with multiple chronic comorbidities.